Programmable Living Cell Therapeutics Market - Strategic Insights and Forecasts (2026-2031)

Programmable Living Cell Therapeutics Market is set to grow at a CAGR of 17.60%, moving from USD 6.5 billion in 2026 to USD 14.6 billion by 2031.

Regulatory maturity and structured clinical evidence define the therapeutic landscape of programmable living cell therapies today, rather than experimental proof of concept. The U.S. Food and Drug Administration’s Centre for Biologics Evaluation and Research (CBER) is establishing this foundation through multiple draft guidance documents about CAR-T design; safety of genomic editing; post-marketing evidence generation; and requirements for next-generation sequencing of edited cell products, and standards for developing CAR-Ts targeting rare and solid tumours by 2025–2026. The FDA has already licensed more than 30 cell and gene-based therapeutic products in the areas of oncology, rare disease, and genetic disorders that are CAR-Ts, in vivo gene therapies, and engineered stem cell derivatives. The regulatory foundation for these products is essential, as it creates reproducible paths for increasingly complex programmable cell systems, including multi-edited constructs and logic-based constructs.

The 2025 FDA scientific workshop on cellular therapy indicated a major change in strategy when generating evidence for the use of less traditional approaches to clinical validation in small patient groups with more detailed mechanistic justification, versus a historical focus on using large data sets. This shift reflects a growing trend of using individualised and genomic modifications to develop therapies for patients with limited populations. Based on reporting from federal data bases and product registries, as well as the data compiled by the FDA through the approval of gene modification therapies, there is a continued significant increase in the number of approved gene therapy products targeting haematologic malignancies; with a further increase in the approval for gene-editing stem cell therapies for the treatment of hemoglobinopathies projected before the end of 2025, indicating the move toward curative treatments for rare illnesses. As a result, there continues to be tremendous growth within the gene therapy marketplace that is fueled by 3 primary trending factors: Increasing numbers of approved therapies from the FDA with a wider variety of modalities, a more thorough and stringent review process for all the submitted data associated with prospective new therapies; and the FDA's rapid review and approval processes for the use of existing FDA-approved therapies in conjunction with the new therapies.

Market Analysis

Growth Drivers

• The FDA’s approval of gene therapies for Rare Disease indications validates the strength of the pipeline for gene therapies moving forward, expanding potential indications. With the recent 2025-2026 approvals of gene-edited therapies for immune and haematological disorders, such as Wiskott-Aldrich syndrome, we now have evidence of measurable clinical benefit in ultra-rare patient populations. As an example, one of the recently FDA-approved therapies demonstrated a 93% reduction in infection rate in treated patients based on clinical information reviewed by the FDA. This level of clinical efficacy then continues to provide regulatory confidence in programmable cell platforms beyond just the cancer indication area, as well as providing for potential therapeutic options to the treatment of all forms of immune deficiency, haemoglobin disorders, and pediatric genetic disease. The growth potential is not through volume, but rather, through the expansion of clinical indications in response to small clinical studies with high clinical impact that have been accepted by the regulatory authority.

• The FDA’s expanding regulatory framework on cell and gene therapy is speeding up how quickly we can take these therapies from the lab to the clinic: The U.S. FDA has put forth several 2025-2026 draft guidance documents around the specific areas of CAR-T design, genetically modified products, and clinical trials that will occur in small populations. The agency issued new guidance on “Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations,” and updated requirements for determining post-approval safety-tracking evidence. The addition of these new structures helps eliminate uncertainty for developers who are working on programmably engineered living cell systems, particularly when it comes to developing autologous cells and therapies that are patient-specific. This also signals that the FDA is moving toward establishing adaptive pathways for regulatory clearance, as opposed to relying on the historical large-population trial framework. As a result, engineered and genetically modified immune cells and stem cell-derived products will progress from IND to BLA at a much quicker rate, especially within oncology and rare disease conditions with limited patient populations.

• Government-backed manufacturing infrastructure programs are reducing scale-up constraints: Regenerative medicine manufacturing is now a national-level funding priority across multiple jurisdictions. In Japan, the Ministry of Economy, Trade and Industry has allocated over 15.8 billion yen (~$100 million) in 2025 budgets to support cell and gene therapy manufacturing infrastructure and CDMO expansion. Similar U.S. and NIH-linked initiatives support standardised GMP facilities and centralised manufacturing ecosystems for cellular therapies. These programs directly target one of the key bottlenecks identified in FDA regulatory reviews: Chemistry, Manufacturing, and Controls (CMC) complexity. The outcome is improved scalability for autologous and allogeneic programmable cell systems, reducing production fragmentation and enabling multi-site clinical deployment.

• NIH–FDA coordinated rare disease acceleration programs are expanding programmable therapy pipelines: The National Institutes of Health and FDA have jointly supported initiatives such as the Bespoke Gene Therapy Consortium aimed at accelerating gene therapy development for thousands of rare diseases, most of which currently lack approved curative treatments. This collaboration focuses on streamlining vector design, manufacturing standardization, and regulatory alignment for individualized therapies. It is particularly relevant for programmable living cell therapeutics, where patient-specific engineering is required. The driver effect is structural pipeline expansion into ultra-rare indications that were previously commercially unviable, enabling programmable cell platforms to evolve from oncology-centric tools into multi-disease therapeutic systems.

Restraints and Opportunities

• Variability of the chemistry, manufacturing and controls requirements (CMC), variability due to complexity of manufacturing autologous therapeutics; review of biologics (2025) from FDA: Autologous CAR-Ts are subject to chemistry, manufacturing, and controls but have unique patient-specific batch production with the average timeline between vein and vein still at 14-21 days even after optimising processes. According to FDA inspection summaries, there is a lack of consistency in batches, component and viral vector variability; along with a chain of identity issues, which represent major deficiencies in all Biological License Applications. These deficiencies create structural bottlenecks to the ability to commercially scale therapies from multiple sites. In contrast to traditional biologics, because each patient-specific batch is treated as a unique product, reproducibility is key from a regulatory perspective. Additionally, with the FDA's 2025 emphasis on real-time release testing and enhancing post-market surveillance, the developer’s operational burden will increase.

• Restricted ability to scale clinically beyond controlled oncology centres: Gene therapies and CAR-Ts approved by the FDA are only available in certified treatment centres due to known safety risks from cytokine release syndrome and neurotoxicity (CAR-Ts). The FDA's Risk Evaluation and Mitigation Strategies (REMS) programs mandate that a provider must be trained to use IFREADY ([Intensive Care Ready] and have an adequate infusion setup/certification; as such, they can only scale geographically within a controlled environment. For example, in 2025, approved products remain heavily concentrated in oncology hospitals (vs. distributed throughout other healthcare facilities). The FDA's clinical guidance for these therapies continues to mandate structured patient monitoring for at least 7–14 days after infusion. Therefore, the delivery model used for gene therapies and CAR-Ts remains primarily based around a controlled environment, thereby restricting the commercial growth opportunities these therapies have despite increasing demand for patients from earlier and newer line indications.

• Expanding gene-targeted curative therapies into rare disease ecosystems: Regulatory acceptance of gene-targeted therapies for severely rare conditions indicates that we will see increased access to companies making curative therapeutics available to patients with ultra-rare conditions following FDA approvals in 2025-2026 for gene-targeted therapies for Wiskott-Aldrich syndrome and sickle cell anaemia. Data sets presented by the FDA demonstrate that 90% of patients treated with gene-targeted therapies were able to achieve some degree of hematologic recovery from their illnesses, as well as that patients with hemoglobinopathies are expected to see long-lasting improvements in the form of hematologic correction. The FDA is assisting with the development of these therapeutics through various grant programs, including the NIH's support of a variety of rare disease grant initiatives and the Bespoke Gene Therapy Consortium, which is working to help standardise the development pathways for personalised gene therapies. As a result of all these initiatives, there is a large opportunity for programmable cell platforms to move into thousands of genetic disorders that do not currently have any validated therapeutic options, causing the market to shift to curative, one-time-only therapies.

• Acceleration of platform and modular cell engineering supported by regulatory bodies: The FDA's projected 2025 guidance for cell and gene therapy development provides a detailed overview of the modular development process for cell-based therapies, specifically, through the reuse of validated components and systems such as viral vectors, gene editing technologies, and CAR backbones for multiple indications. By taking this modular approach to cell therapy development, the amount of time it takes to go from an investigational new drug application to a biologics license application for new programmable cell products will be greatly decreased. Furthermore, NIH and FDA collaborative efforts are also focusing on building standard vector libraries and standardising manufacturing protocols for both CAR systems and CRISPR systems that will further support modular development and thereby support the ability to build an engineered living cell system across areas such as oncology, autoimmune diseases, and regenerative medicine while using standardised regulatory pathways to develop the next generation of programmable therapeutics with minimal friction.

Government Regulations

Key Development

• April 2026: The U.S. Food and Drug Administration (FDA) has granted traditional (full) approval to Kite’s CAR T-cell therapy, Tecartus® (brexucabtagene autoleucel), for adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Market Segmentation

The market is segmented by therapy type, technology, application, end user and geography.

By Therapy Type

U.S. FDA Centre for Biologics Evaluation and Research-approved product classes apply to therapy segmentation based on the respective therapy product types rather than commercial categorisation, effective 2025. FDA-recognised cellular and gene therapy products as of 2025 include CAR-T therapies (e.g., YESCARTA, KYMRIAH), gene-modified autologous stem cell therapies for sickle cell disease (e.g., CASGEVY), NK cell and tumour-infiltrating lymphocyte (TIL) therapies (e.g., AMTAGVI), and regenerative engineered tissues (e.g., ELEVIDYS) for Duchenne muscular dystrophy. Segmentation is based upon the mechanism of action regardless of the indication of use. CAR-T therapies currently dominate hematologic oncology, and gene-edited stem cells currently enable curative hematologic applications, while additional NK and TIL-based technologies have been historically limited by the earlier stages of FDA regulation but are now being explored for use against solid tumour indications. Separately, other tissues engineered to regenerate, and repair have a unique FDA classification pathway as gene therapy biologics. Segmentation is increasingly headed toward platform therapies where a single engineered cell construct can be applied to multiple indications based on FDA's Modular Product Development Guidance.

By Technology

Technology segmentation is founded upon existing FDA draft guidance documents for gene editing, CAR design and post-approval evidence generation issued in 2025-2026. Based upon the 2024 update to the FDA's "Human Gene Therapy Products Incorporating Genome Editing" guidance, CRISPR-based gene editing is explicitly regulated (2024 revision has expanded enforcement). For example, the gene therapy product known as federally recognised cellular and gene therapy, including gene-modified autologous stem cell (for example, CASGEVY) based therapy has been developed for the treatment of sickle cell disease and allows for base editing and multiplexed modifications. The second layer of technology is based upon the use of Synthetic Gene Circuits and therefore, all CAR-T systems being developed as gatekeepers to activate antigen specificity and safety switches for therapeutic application are regulated under CAR-T Development Guidance from the FDA. Additionally, means of programming RNA expression that are intended to be transiently expressed have been reviewed.

By Application

Application segmentation follows FDA-approved indications listed across biologics licenses. Oncology remains dominant, driven by CAR-T approvals for B-cell lymphomas, multiple myeloma, and melanoma therapies such as AMTAGVI and CARVYKTI. Autoimmune diseases are emerging following NIH-supported translational studies and early FDA-reviewed datasets showing durable B-cell depletion responses in refractory systemic lupus and related disorders. Rare genetic disorders represent the fastest-expanding application, validated by CASGEVY for sickle cell disease and beta-thalassemia under FDA curative therapy designation frameworks. Infectious and metabolic disease applications remain investigational but are supported by NIH-funded programs targeting viral reservoirs and metabolic pathway engineering. The FDA’s 2025 rare disease trial design guidance explicitly enables smaller, mechanistic trials for ultra-rare conditions, accelerating expansion beyond oncology. This segmentation reflects a shift from oncology-first adoption to systemic disease reprogramming.

By End User

End-user segmentation is defined by FDA Risk Evaluation and Mitigation Strategy (REMS) requirements and clinical administration controls embedded in approved product labelling. Hospitals and speciality certified treatment centres remain primary endpoints for CAR-T and gene therapy administration due to mandated post-infusion monitoring for toxicities such as CRS and neurotoxicity. Biopharmaceutical companies function as both developers and manufacturing operators under FDA biologics license requirements, particularly for autologous therapies where chain-of-identity and GMP compliance are critical. NIH and FDA-supported manufacturing modernisation programs further reinforce this segment through standardised vector and cell processing frameworks. Research institutes, including NIH-funded translational centres, drive early-stage IND submissions and mechanism validation studies, especially under FDA’s small population trial guidance introduced in 2025. This structure is tightly regulated rather than demand-driven, with end-user roles defined by compliance intensity, manufacturing responsibility, and clinical administration capability.

Regional Analysis

North America Market Analysis

North America remains the most advanced regulatory and clinical hub for programmable living cell therapeutics, led by the U.S. FDA. The region accounts for the largest share of global CAR-T clinical activity, with over 3,500 registered trials in the United States alone as of 2025. The FDA has already approved multiple CAR-T and gene-edited therapies, including CD19 and BCMA-targeted products, creating a mature commercialisation pathway. NIH-supported programs such as the Bespoke Gene Therapy Consortium are expanding into ultra-rare disease engineering, reinforcing pipeline depth. Manufacturing capacity and REMS-certified centres remain concentrated in the U.S., enabling faster adoption but limiting decentralisation.

South America Market Analysis

South America is in early-stage clinical and regulatory adoption, with Brazil emerging as the primary entry point for programmable cell therapies through participation in global CAR-T clinical trials. Regulatory activity remains limited compared to FDA or EMA frameworks, but integration with multinational studies is increasing exposure to advanced therapies. NIH and FDA trial registries indicate that most South American involvement is centred on oncology bridging studies rather than independent approvals. Infrastructure constraints, particularly in GMP-certified cell manufacturing, restrict localised production. However, participation in international trial networks is steadily increasing patient access to investigational CAR-T and gene-modified therapies in major urban oncology centres.

Europe Market Analysis

Europe operates under the European Medicines Agency advanced therapy medicinal product framework, which has approved 26 ATMPs, including gene therapies and CAR-T products as of 2024–2025 updates. The region shows a higher proportion of Phase III cell therapy trials compared to other geographies, indicating strong late-stage clinical validation.

Countries such as Germany, the UK, and France host CAR-T centres of excellence integrated into national health systems. EMA approvals are centralised, but reimbursement variability remains a constraint on access. The region also demonstrates a strong focus on standardised post-market surveillance frameworks, particularly for long-term gene therapy safety monitoring.

Middle East and Africa Market Analysis

The Middle East and Africa region remains the least penetrated but structurally evolving market for programmable living cell therapeutics. Adoption is primarily concentrated in Gulf countries with advanced tertiary care infrastructure. Clinical access is largely dependent on international referral programs and participation in multinational oncology trials rather than domestic approvals. Regulatory frameworks are still developing compared to FDA or EMA systems, particularly for gene-edited therapies. Infrastructure gaps in GMP manufacturing and limited REMS-equivalent systems constrain commercial deployment. However, increasing investment in oncology hospitals and cross-border clinical partnerships is gradually improving access to CAR-T therapies in select high-income healthcare hubs.

Asia Pacific Market Analysis

Asia Pacific is the fastest-expanding region for programmable cell therapies, driven by China, Japan, and South Korea. China alone accounts for over 3,300 cell therapy clinical trials, nearly matching the United States in scale. The region has over 10 domestically approved CAR-T products, reflecting strong regulatory agility and manufacturing cost advantages. Japan and South Korea contribute through accelerated regenerative medicine pathways and government-backed cell manufacturing programs. India is emerging with cost-access CAR-T models. Overall, the region is characterized by high trial density, rapid regulatory adaptation, and strong emphasis on scalable, lower-cost manufacturing models compared to Western markets.

List of Companies

• Novartis

• Bristol Myers Squibb

• Gilead Sciences (Kite Pharma)

• Johnson & Johnson (Janssen Biotech)

• Pfizer

• Amgen

• Sanofi

• AstraZeneca

• Takeda

• Astellas Pharma

• Vertex Pharmaceuticals

• bluebird bio

• Legend Biotech

• Autolus Therapeutics

Novartis

Novartis remains structurally significant in programmable living cell therapeutics through its first-generation CAR-T asset KYMRIAH, the first FDA-approved CAR-T therapy. The company continues to emphasise manufacturing scale through its integrated CAR-T supply chain spanning multiple continents. Novartis also highlights next-generation CAR-T development using its T-Charge platform, designed to improve cell expansion and persistence while reducing ex vivo processing time. The FDA’s 2025 removal of REMS requirements for CAR-T therapies improves operational flexibility, supporting broader outpatient administration models already demonstrated in KYMRIAH’s real-world use cases.

Gilead Sciences (Kite Pharma)

Gilead Sciences, through its Kite subsidiary, is a leading commercial player in CAR-T manufacturing, particularly with YESCARTA and TECARTUS. Company disclosures emphasise strong commercial scale-up with consistent manufacturing turnaround improvements and expansion into earlier-line lymphoma indications supported by FDA approvals. Kite’s pipeline focuses on next-generation engineered cell therapies, including allogeneic and solid tumour CAR constructs. The company has also invested in automated manufacturing systems to reduce vein-to-vein time, a key FDA-identified bottleneck in 2025 regulatory discussions. Kite’s operational advantage is its vertically integrated manufacturing and clinical network, which supports rapid therapy deployment across U.S. FDA-certified centres, making it one of the most execution-heavy players in the programmable cell therapy ecosystem.

Bristol Myers Squibb

Bristol Myers Squibb has built its programmable cell therapy portfolio through multiple FDA-approved assets including Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T). Company communications highlight strong expansion into multiple myeloma and lymphoma treatment lines following FDA label extensions. BMS has emphasized dual-target CAR architecture and improved safety management protocols, particularly around cytokine release syndrome mitigation. The company continues to invest in manufacturing optimization to address the FDA-identified complexity of CAR-T production workflows, including separate CD4/CD8 processing improvements in earlier programs. In 2025 regulatory context, BMS benefits from FDA easing of REMS restrictions, enabling more flexible administration models while maintaining strict post-treatment monitoring frameworks embedded in its commercial CAR-T portfolio.

Analyst View

The programmable living cell therapeutics market is entering a phase where scientific feasibility is no longer the constraint; execution is. Clinical outcomes reviewed by the U.S. Food and Drug Administration have already validated CAR-T and gene-edited therapies as high-efficacy interventions, particularly in hematologic malignancies and rare genetic disorders. The real differentiation now sits in manufacturing control, turnaround time, and the ability to standardize highly individualised products under strict regulatory frameworks.

Programmable Living Cell Therapeutics Market Scope: